Investor Overview

Webcast ImageWebcast
Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series (Live)
09/28/16 at 2:05 p.m. ET
Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
Wednesday, September 28, 2016 2:05 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
PTI (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$15.42
Change (%) Stock is Up 0.22 (1.45%)
Volume573,355
Data as of 09/23/16 4:00 p.m. ET
Corporate Profile

Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Our initial therapeutic focus is on cystic fibrosis, or CF, which is caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. ... More >>

Recent NewsMore >>
Proteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Conference
September 22, 2016
Read More


Proteostasis Therapeutics to Present at Upcoming Investor Conferences
September 15, 2016
Read More


Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock
September 14, 2016
Read More


Upcoming EventsMore >>
Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
Wednesday, September 28, 2016 2:05 p.m. ET

Jefferies Cystic Fibrosis Summit
Thursday, September 29, 2016 8:45 a.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
INVESTORS & MEDIA